Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...
In tandem, public perceptions of these medications are evolving significantly. With celebrities crediting the new treatments ...
Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...
If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...
Lots of people want to lose weight but they don't necessarily want to take regular injections to do it. That's the finding of ...
A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such ...
Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.
A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs ...
Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the ...
That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...
One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...
Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback